Dual HER2 inhibition and paclitaxel in metastatic breast cancer

被引：0
|
作者：
Brower, Vicki
机构：
来源：
LANCET ONCOLOGY | 2015年 / 16卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(14)71201-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E57 / E57
页数：1
相关论文
共 50 条
  • [21] Proliferation Index in "HER2 Low" Metastatic Breast Cancer
    Hrizat, A. S.
    Brachtel, E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S13 - S14
  • [22] Novel therapies for metastatic HER2 positive breast cancer
    Cossetti R.J.D.
    Gelmon K.A.
    Current Breast Cancer Reports, 2013, 5 (4) : 331 - 340
  • [23] Phase I study of dasatinib in combination with trastuzumab and paclitaxel in patients with HER2 positive metastatic breast cancer
    Gil, M.
    Martin, M.
    Antolin, S.
    Trigo, J. M.
    Guerrero, A.
    Vidal, L.
    Urruticoechea, A.
    Pandiella, A.
    Hernando, A.
    Ocana, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S180 - S180
  • [24] Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Seidman, AD
    Fornier, MN
    Esteva, FJ
    Tan, L
    Kaptain, S
    Bach, A
    Panageas, KS
    Arroyo, C
    Valero, V
    Currie, V
    Gilewski, T
    Theodoulou, M
    Moynahan, ME
    Moasser, M
    Sklarin, N
    Dickler, M
    D'Andrea, G
    Cristofanilli, M
    Rivera, E
    Hortobagyi, GN
    Norton, L
    Hudis, CA
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2587 - 2595
  • [25] HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plus trastuzumab (GTH)
    Colomer, R
    Mayordomo, JI
    Calvo, L
    Hornedo, J
    Carabantes, F
    Gil, M
    Cortes-Funes, H
    Martin, B
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S127 - S128
  • [26] Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer.
    Colomer, R
    Mayordomo, JI
    Calvo, L
    Hornedo, J
    Carabantes, F
    Gil, M
    Martin, B
    Cortes-Funes, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 61S - 61S
  • [27] Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    Trusolino, Livio
    Martino, Cosimo
    Bencardino, Katia
    Lonardi, Sara
    Leone, Francesco
    Zagonel, Vittorina
    Bertotti, Andrea
    Valtorta, Emanuele
    Siravegna, Giulia
    Amatu, Alessio
    Vanzulli, Angelo
    Regge, Daniele
    Ghezzi, Silvia
    Ciardiello, Fortunato
    Veronese, Silvio
    Comoglio, Paolo Maria
    Bardelli, Alberto
    Marsoni, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
    Limbach, A. A. Lott
    Downs-Kelly, E. P.
    Papouchado, B. G.
    Tubbs, R. R.
    Lanigan, C.
    Booth, C. N.
    LABORATORY INVESTIGATION, 2012, 92 : 52A - 52A
  • [29] HER2 Dual ISH Determination of HER2 Gene Status in Breast Cancer: Interobserver Reproducibility
    Limbach, A. A. Lott
    Downs-Kelly, E. P.
    Papouchado, B. G.
    Tubbs, R. R.
    Lanigan, C.
    Booth, C. N.
    MODERN PATHOLOGY, 2012, 25 : 52A - 52A
  • [30] Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
    Emde, Anna
    Mahlknecht, Georg
    Maslak, Kerstin
    Ribba, Benjamin
    Sela, Michael
    Possinger, Kurt
    Yarden, Yosef
    TRANSLATIONAL ONCOLOGY, 2011, 4 (05): : 293 - 300
12345